http://www.pharmacist.com/AM/Templa...mplate=/CM/ContentDisplay.cfm&ContentID=25967
The third dipeptidyl peptidase-4 (DPP-4), linagliptin (Tradjenta—Boehringer Ingelheim, Eli Lilly), has been approved by FDA for the treatment of adult patients with type 2 diabetes as an adjunct to diet and exercise. It has been studied both as monotherapy and in combination with sulfonylureas, metformin, and pioglitazone (Actos—Takeda). Although linagliptin is the third agent to enter the DPP-4 class in the United States, following the approval of sitagliptin (Januvia—Merck) and saxagliptin (Onglyza—Bristol-Myers Squibb), this agent has some unique features.
The third dipeptidyl peptidase-4 (DPP-4), linagliptin (Tradjenta—Boehringer Ingelheim, Eli Lilly), has been approved by FDA for the treatment of adult patients with type 2 diabetes as an adjunct to diet and exercise. It has been studied both as monotherapy and in combination with sulfonylureas, metformin, and pioglitazone (Actos—Takeda). Although linagliptin is the third agent to enter the DPP-4 class in the United States, following the approval of sitagliptin (Januvia—Merck) and saxagliptin (Onglyza—Bristol-Myers Squibb), this agent has some unique features.
